tetano
Editor, Senior Moderator
PLoS One
. 2021 Jul 14;16(7):e0254563.
doi: 10.1371/journal.pone.0254563. eCollection 2021.
Sero-surveillance for SARS-CoV-2 infection among healthcare providers in four hospitals in Thailand one year after the first community outbreak
Wanitchaya Kittikraisak[SUP] 1 [/SUP], Phunlerd Piyaraj[SUP] 2 [/SUP], Apichat Vachiraphan[SUP] 3 [/SUP], Thanapat Wongrapee[SUP] 4 [/SUP], Somsak Punjasamanvong[SUP] 5 [/SUP], Taweewun Hunsawong[SUP] 6 [/SUP], Chalinthorn Sinthuwattanawibool[SUP] 1 [/SUP], Chaniya Leepiyasakulchai[SUP] 7 [/SUP], Pornsak Yoocharoen[SUP] 8 [/SUP], Eduardo Azziz-Baumgartner[SUP] 9 [/SUP], Joshua A Mott[SUP] 1 9 [/SUP], Suthat Chottanapund[SUP] 8 [/SUP]
Affiliations
Abstract
Background: Thailand was the first country outside China to report SARS-CoV-2 infected cases. Since the detection of the first imported case on January 12th, 2020 to the time this report was written, Thailand experienced two waves of community outbreaks (March-April 2020 and December 2020-March 2021). We examined prevalence of SARS-CoV-2 seropositivity among healthcare providers (HCPs) in four hospitals approximately one year after SARS-CoV-2 first detected in Thailand. By March 2021, these hospitals have treated a total of 709 coronavirus disease 2019 (COVID-19) patients.
Methods: Blood specimens, collected from COVID-19 unvaccinated HCPs during January-March 2021, were tested for the presence of SARS-CoV-2 immunoglobulin G (IgG) antibodies to nucleocapsid (IgG-nucleocapsid) and spike (IgG-spike) proteins using Euroimmune® enzyme-linked immunosorbent assays.
Results: Of 600 HCPs enrolled, 1 (0.2%) tested positive for the SARS-CoV-2 IgG-spike antibodies, but not the IgG-nucleocapsid.
Conclusion: The presence of SARS-CoV-2 IgG antibodies was rare in this sample of HCPs, suggesting that this population remains susceptible to SARS-CoV-2 infection.
. 2021 Jul 14;16(7):e0254563.
doi: 10.1371/journal.pone.0254563. eCollection 2021.
Sero-surveillance for SARS-CoV-2 infection among healthcare providers in four hospitals in Thailand one year after the first community outbreak
Wanitchaya Kittikraisak[SUP] 1 [/SUP], Phunlerd Piyaraj[SUP] 2 [/SUP], Apichat Vachiraphan[SUP] 3 [/SUP], Thanapat Wongrapee[SUP] 4 [/SUP], Somsak Punjasamanvong[SUP] 5 [/SUP], Taweewun Hunsawong[SUP] 6 [/SUP], Chalinthorn Sinthuwattanawibool[SUP] 1 [/SUP], Chaniya Leepiyasakulchai[SUP] 7 [/SUP], Pornsak Yoocharoen[SUP] 8 [/SUP], Eduardo Azziz-Baumgartner[SUP] 9 [/SUP], Joshua A Mott[SUP] 1 9 [/SUP], Suthat Chottanapund[SUP] 8 [/SUP]
Affiliations
- PMID: 34260638
- DOI: 10.1371/journal.pone.0254563
Abstract
Background: Thailand was the first country outside China to report SARS-CoV-2 infected cases. Since the detection of the first imported case on January 12th, 2020 to the time this report was written, Thailand experienced two waves of community outbreaks (March-April 2020 and December 2020-March 2021). We examined prevalence of SARS-CoV-2 seropositivity among healthcare providers (HCPs) in four hospitals approximately one year after SARS-CoV-2 first detected in Thailand. By March 2021, these hospitals have treated a total of 709 coronavirus disease 2019 (COVID-19) patients.
Methods: Blood specimens, collected from COVID-19 unvaccinated HCPs during January-March 2021, were tested for the presence of SARS-CoV-2 immunoglobulin G (IgG) antibodies to nucleocapsid (IgG-nucleocapsid) and spike (IgG-spike) proteins using Euroimmune® enzyme-linked immunosorbent assays.
Results: Of 600 HCPs enrolled, 1 (0.2%) tested positive for the SARS-CoV-2 IgG-spike antibodies, but not the IgG-nucleocapsid.
Conclusion: The presence of SARS-CoV-2 IgG antibodies was rare in this sample of HCPs, suggesting that this population remains susceptible to SARS-CoV-2 infection.